Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 7/20 | 0.61 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.61 |
| ▸ | HRH1 | P35367 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.56 |
| ▸ | GPR183 | P32249 | 5/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 4/20 | 0.52 |
| ▸ | F10 | P00742 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6801435 | 0.85 | F10 (0.71) | F10 | |
| SCHEMBL17938656 | 0.84 | HRH4 (0.67) | HRH4HRH3HRH1KMT2AGPR183 | |
| SCHEMBL16599390 | 0.84 | HRH4 (0.76) | HRH4HRH3HRH1KMT2AGPR183 | |
| SCHEMBL17954163 | 0.83 | HRH4 (0.65) | HRH4HRH3HRH1KMT2AGPR183 | |
| SCHEMBL17954162 | 0.82 | HRH4 (0.73) | HRH4HRH3HRH1KMT2AGPR183 | |
| SCHEMBL17954188 | 0.82 | HRH4 (0.73) | HRH4HRH3HRH1KMT2AGPR183 | |
| SCHEMBL6804360 | 0.81 | F10 (0.72) | HRH4HRH3HRH1KMT2AGPR183 | |
| SCHEMBL16599089 | 0.81 | HRH4 (0.71) | HRH4HRH3HRH1KMT2AGPR183 | |
| SCHEMBL17938630 | 0.80 | HRH4 (0.86) | HRH4HRH3HRH1KMT2AGPR183 | |
| SCHEMBL17938639 | 0.80 | HRH4 (0.70) | HRH4HRH3HRH1KMT2AGPR183 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040082786-A1 | Piperazine based inhibitors of factor xa | MILENNIUM PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082786-A1 | Piperazine based inhibitors of factor xa | TFPI, F11, F12 | HRH4 2427/4885HRH3 1373/4885HRH1 745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.